Cisatracurium Besylate Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Cisatracurium Besylate Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on May 6, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Hospira, Inc., A Pfizer Company
- Package NDC
- 0409-1103-01
- Dosage Form
- Injection
- Presentation
- Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)
- Initial Posting
- May 6, 2026